Invitae

Ciitizen Corporation is a healthcare technology company based in Palo Alto, California, that operates a digital platform designed to empower patients to collect, organize, and share their personal health information, including genomic data and lab results. Founded in 2017, Ciitizen aims to give individuals control over their complete health records, facilitating the sharing of this information with caregivers, researchers, and other relevant parties. The platform addresses the limitations of existing health data portals, which often provide only minimal information and rely on labor-intensive processes to extract insights from unstructured data. By normalizing diverse health information into actionable formats, Ciitizen enhances transparency and accessibility for patients and healthcare providers alike. The company is led by CEO Anil Sethi and is supported by a prominent investment team.

Genosity is a life science biotechnology company focused on providing tools and services for clinical research applications of genomics. They provide novel software solutions and laboratory services for both somatic and germline applications to enable their strategic partners to fully realize the value of precision medicine for both the research and clinical markets.

One Codex is a data platform focused on applied microbial genomics, offering bioinformatics solutions that facilitate advancements in clinical diagnostics, food safety, and biosecurity. The company specializes in developing a robust and scalable bioinformatics platform that streamlines metagenomics and microbial genomics analysis. Emphasizing user-friendliness, One Codex provides applied microbiologists with rapid access to microbiome analysis through its comprehensive microbial reference database. This approach allows researchers and professionals to leverage genomic data effectively, enhancing their ability to address challenges in various sectors related to microbiology.

ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.

Genelex Corporation is a DNA testing laboratory based in Seattle, Washington, specializing in pharmacogenetic testing and personalized medication management. Founded in 1987, the company focuses on providing DNA sensitivity testing and utilizes its GeneMedRx software, which assesses potential drug-drug and drug-gene interaction risks based on genetic data. Genelex offers a range of services, including parentage and forensic DNA testing, ancestry DNA testing, and predictive genetic testing. Additionally, the company provides at-home and legally admissible DNA tests, such as maternity and paternity tests, and twin zygosity tests. With a commitment to preventing adverse drug events, Genelex combines innovative analytics software and advanced laboratory facilities to support healthcare providers in making informed prescribing decisions. As of April 2020, Genelex operates as a subsidiary of Invitae Corporation.

Diploid is a biotechnology services provider specializing in clinical genome interpretation software aimed at diagnosing genetic disorders and addressing rare diseases. The company's innovative software leverages artificial intelligence to analyze human genome data, transforming raw genetic information into comprehensive reports that identify novel variants responsible for genomic abnormalities. This capability allows hospitals and clinical laboratories to enhance their diagnostic efficiency by outsourcing the complex task of clinical genome interpretation, ultimately leading to improved diagnostic rates and reduced workload for medical professionals.

Clear Genetics, Inc. is a digital health company based in San Francisco, California, that specializes in providing genetic counseling services to women, healthcare providers, and health systems. Established in 2016, the company offers Clearancy, a web application designed to deliver personalized genetic information for patients undergoing genetic testing and their healthcare practitioners. Clear Genetics collaborates with health systems, laboratories, and academic institutions to enhance patient access to genetic counseling and testing across various medical specialties, including prenatal care, cardiology, carrier screening, hereditary cancer, and pediatrics. As of November 2019, Clear Genetics operates as a subsidiary of Invitae Corporation.

Jungla Inc., established in 2016 and headquartered in South San Francisco, is a biotechnology company specializing in molecular function software for healthcare and pharmaceutical industries. It optimizes disease diagnosis by developing advanced functional genomics, computational biophysics, and computer science technologies. Jungla's platform proactively assesses genetic variant risks, providing quantitative insights to complement observational data. This enhances clinical genetic testing accuracy and delivers robust, scalable results. As of July 2019, Jungla operates as a subsidiary of Invitae Corporation.

Singular Bio, Inc. is a San Francisco-based company established in 2012 that specializes in diagnostic testing for personalized medicine. The company has developed a proprietary platform for single molecule analysis of DNA, which enables highly sensitive detection of various common health conditions. Singular Bio’s technology combines advanced optical methods with custom molecular biology and chemistry, allowing for cost-effective and rapid screening processes. The company's mission is to broaden access to essential healthcare information by making advanced genetic testing widely available, ultimately facilitating early detection and improved health outcomes for diverse populations. As of June 2019, Singular Bio operates as a subsidiary of Invitae Corporation.

Good Start Genetics, Inc. is a molecular diagnostics company based in Cambridge, Massachusetts, founded in 2007. It specializes in genetic screening for inherited diseases, aiming to transform reproductive medicine by providing actionable information to physicians and patients. The company offers a range of services, including EmbryVu, a preimplantation genetic screening test designed to enhance in vitro fertilization outcomes by identifying suitable embryos for implantation. Additionally, Good Start Genetics provides a comprehensive array of genetic carrier screening tests through its GoodStart Select program, utilizing advanced next-generation DNA sequencing technology along with other established genetic screening methods. This focus on high carrier detection rates and commitment to customer care and genetic counseling positions the company as a leader in the field of pre-pregnancy genetic testing and diagnostics. As of August 2017, Good Start Genetics operates as a subsidiary of Invitae Corporation.

CombiMatrix Corporation, founded in 1995 and headquartered in Irvine, California, is a provider of clinical molecular diagnostic laboratory services in the United States. The company specializes in pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. CombiMatrix employs advanced technologies such as single nucleotide polymorphism, chromosomal microarray analysis, next-generation sequencing, fluorescent in situ hybridization, and high-resolution karyotyping to deliver its diagnostic services. These methods allow for the detection of genetic abnormalities that traditional methodologies may overlook, thereby enhancing patient care. CombiMatrix serves a diverse clientele, including commercial insurance companies, healthcare institutions, government payors, and individual patients. As of November 2017, CombiMatrix operates as a subsidiary of Invitae Corporation, continuing its commitment to advancing genetic diagnostics.

CancerGene Connect is a developer of a cloud-based genetic assessment platform that focuses on collecting, assessing, and managing genetic family histories. The platform streamlines the genetic counseling process by facilitating the collection of family medical histories and cancer risk assessments. This innovative technology allows clinicians to dedicate more time to addressing patient risks by reducing the time spent on data organization. With ongoing improvements, CancerGene Connect enhances its capabilities in pedigree generation and risk modeling, ultimately benefiting thousands of patients and healthcare practices.

AltaVoice, established in Silicon Valley since 2007, specializes in operating Patient Insights Networks (PINs). These platforms facilitate the collection, curation, and sharing of patient and clinician-reported health data. The company collaborates with drug developers, advocacy organizations, academic researchers, and patients to accelerate medical advancements by breaking down data silos. AltaVoice has worked with over 100 advocacy groups, NIH, PCORI, and numerous biotech and pharmaceutical companies, creating programs for more than 400 diseases. Notably, the company was invited to participate in the Cancer Moonshot events at the White House in recognition of its pioneering work.